A LinkedIn post from ThinkCyte highlights the company’s presence at the SLAS 2026 conference in Boston, where it is showcasing its Ghost Cytometry technology for high-speed, label-free cell sorting with real-time AI analysis. The post points to applications in streamlining drug discovery, phenotypic screening workflows, CRISPR screening, and isolation of rare cell populations.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also references two scientific posters focused on phenotyping phagocytosing immune cells and morphometric profiling for potential senescence biomarkers, suggesting ongoing R&D efforts tied to its VisionSort platform. For investors, this visibility at a specialized industry conference may support business development, validate the technology among key pharma and biotech decision-makers, and signal a focus on advanced cell analysis markets such as regenerative medicine and drug discovery.